Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas

NCT00613223 is registered in ClinicalTrials.gov with Annick Desjardins as lead sponsor.

NCT NCT00613223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00613223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas
Lead sponsor
Annick Desjardins
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
May 31, 2011
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma